Modular Phase II Study to Link Targeted Therapy to Patients With Pathway Activated Tumors: Module 1 - BKM120 for Patients With PI3K-activated Tumors
Phase of Trial: Phase II
Latest Information Update: 21 Oct 2018
Price : $35 *
At a glance
- Drugs Buparlisib (Primary)
- Indications Haematological malignancies; Solid tumours
- Focus Therapeutic Use
- Acronyms SIGNATURE
- Sponsors Novartis Pharmaceuticals
- 07 Nov 2016 Status changed from active, no longer recruiting to completed.
- 01 Aug 2016 Planned End Date changed from 1 May 2016 to 1 May 2017.
- 01 Aug 2016 Planned primary completion date changed from 1 May 2016 to 1 May 2017.